California-based entrepreneur Manny Bojorquez owns several companies, including hyperfastcars.com and ziptuningusa.com. He also leads peaCURE, a company that develops pharmaceutical-grade palmitoylethanolamide (PEA) for use as a pain supplement. Under the leadership of Manny Bojorquez, peaCURE addresses chronic pain using this naturally occurring substance.
PEA, also known as N-2 hydroxyethyl palmitamide, belongs to the N-acylethanolamines (NAE) family. This family is composed of naturally occurring lipids that are biologically active. PEA, along with other NAEs, can act on the cannabinoid receptor in the brain. At the same time, it reduces the amount of activity of the bliss gene FAAH. FAAH breaks down natural cannabinoid anandamide, and reducing its activity creates a calming effect that combats pain and boosts relaxation.
Due to PEA’s interactions with cannabinoid receptors (an action that is similar to cannabidiol), there is a common misconception that it is a cannabinoid as well. To an extent, PEA can be classified as part of the cannabinoid family. However, unlike CBD and THC (both of which are plant cannabinoids found in the cannabis plant), PEA is regarded as an endocannabinoid. This means that the body produces the substance naturally. Neither THC or CBD is naturally produced by the body.
